DHRHealth Institute for Research and Development
News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A Study of AKR-001 in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Study Status:

Closed For Enrollment

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of AKR-001 in subjects with NASH. The purpose of this research study is to assess how well the different doses of AKR-001 work to reduce the amount of fat in the liver.


Principal Investigator
Rama Behara, DO
Akero Therapeutics, Inc
Type of Trial
© 2023 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram